14
Apr
2020
The Pandemic Takes A Certain Kind of Toll on African Americans
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Apr
2020
GSK Partners With Vir on Antibodies, Pfizer With BioNTech on Vaccines, & the Testing Fiasco Continues
Here we are heading into Easter Weekend. We’re the wealthiest country in the world, and the undisputed superpower of biomedicine. Yet we’re still playing a game of catch up against SARS-CoV-2, which apparently our intelligence community knew was emerging around Thanksgiving. Even after months to get our act together, we still don’t have a coordinated national strategy on exactly how... Read More
8
Apr
2020
Facing the Consequences of a Misinformation Pandemic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Apr
2020
George Yancopoulos, That Rarest Of Species – A Physician-Scientist Still In Charge Of A Pharma
Growing up in an academic household (my parents are both professors at Yale Medical School, still engaged, as ever, in dyslexia research), it was perhaps inevitable that, outside of my parents, my first role model was the brilliant President of Yale University, the late Bart Giamatti (you know- Paul’s dad). The elder Giamatti inspired me so much as a teenager... Read More
7
Apr
2020
Rationale for Testing Anticoagulants Against COVID19
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Apr
2020
COVID-19 Models: What Makes Them Tick?
As the COVID-19 pandemic unfolds, questions about its likely course are much on our minds. How long will it last? How bad will it get? And are we doing enough to flatten the curve? These questions are not about the past, but about the future. Models are now frequently cited in public by elected leaders to inform expectations and justify... Read More
6
Apr
2020
I’ve Got a Fund Full of Toilet Paper and I’m Ready to Deal!
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Apr
2020
Where the Puck is Going: Serologic Testing for SARS-CoV-2 Immunity
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Apr
2020
Loss and Grief in the Time of Covid-19
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Apr
2020
Diagnostic Dysfunction for COVID19: Mike Pellini on The Long Run
Today’s guest on The Long Run is Mike Pellini. Mike is a managing partner with Section32, a venture firm that invests in biotech startups. Mike is an expert in diagnostics. He was previously the CEO of Foundation Medicine, a company that looks at a wide range of gene mutations in tumor samples to can act as molecular drivers of cancer.... Read More
2
Apr
2020
A Baffling Coronavirus Response, Arch & Flagship Reload, & Merck Passes 2 Phase IIIs
The world now has more than 1 million confirmed cases of infection with an insidious virus that spreads from person to person with exponential speed, is spread by people who don’t display symptoms, and kills an estimated 1 percent of people who get infected. As the US death toll now exceeds more than 1,000 a day from COVID-19, we are... Read More
2
Apr
2020
COVID-19’s Unexpected Silver Lining: A Chance at Redemption for US Healthcare
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Apr
2020
What’s the Real Risk of Death from COVID19? It Can Be Deceiving
“There are three kinds of lies: lies, damned lies, and statistics,” quote popularized in the US by Mark Twain This is an almost direct follow-up to my latest article for Timmerman Report (“Let it Rip or Shelter at Home?) Usual caveats apply: I am not an epidemiologist, and not a virologist. This is still a new virus for us as... Read More
1
Apr
2020
Building On Our Immunology Understanding, Seeing Reasons for Hope
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Apr
2020
Thinking Ahead: Building a Broad Arsenal Against Infectious Disease
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
31
Mar
2020
The Strategy of Stealth Mode. When to Stay Hidden, When to De-Cloak
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
31
Mar
2020
Diagnostic Test Developer Points to Academic Blind Spot That Hampers Translation
The COVID-19 pandemic has highlighted the need for reliable diagnostic tests for the new SARS-CoV-2 virus, and treatments that can cure or mitigate its devastating effects. To have an impact, these diagnostic tests can’t just work brilliantly in a single academic lab. They ultimately need to be rapidly deployable across this large country with 330 million people. Developing an approach... Read More
31
Mar
2020
Switzerland: What Went Right, and How to Better Prepare for the Second Wave
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
31
Mar
2020
Learning from China, Ramping Up COVID19 Tests to Meet Needs Around the World
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Mar
2020
Cancer Drugmakers Seek to Broaden Use of Tissue-Agnostic Therapies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.